| Literature DB >> 29530390 |
Shota Ichimizu1, Hiroshi Watanabe2, Hitoshi Maeda1, Keisuke Hamasaki1, Yuka Nakamura1, Victor Tuan Giam Chuang3, Ryo Kinoshita1, Kento Nishida1, Ryota Tanaka1, Yuki Enoki1, Yu Ishima4, Akihiko Kuniyasu5, Yoshihiro Kobashigawa6, Hiroshi Morioka6, Shiro Futaki7, Masaki Otagiri8, Toru Maruyama9.
Abstract
Human serum albumin (HSA) is a superior carrier for delivering extracellular drugs. However, the development of a cell-penetrating HSA remains a great challenge due to its low membrane permeability. We report herein on the design of a series of palmitoyl-poly-arginine peptides (CPPs) and an evaluation of their cell-penetrating effects after forming a complex with HSA for use in intracellular drug delivery. The palmitoyl CPPs forms a stable complex with HSA by anchoring itself to the high affinity palmitate binding sites of HSA. Among the CPPs evaluated, a cyclic polypeptide composed of D-dodecaarginines, palmitoyl-cyclic-(D-Arg)12 was the most effective for facilitating the cellular uptake of HSA by HeLa cells. Such a superior cell-penetrating capability is primarily mediated by macropinocytosis. The effect of the CPP on pharmacological activity was examined using three drugs loaded in HSA via three different methods: a) an HSA-paclitaxel complex, b) an HSA-doxorubicin covalent conjugate and c) an HSA-thioredoxin fusion protein. The results showed that cell-penetrating efficiency was increased with a corresponding and significant enhancement in pharmacological activity. In conclusion, palmitoyl-cyclic-(D-Arg)12/HSA is a versatile cell-penetrating drug delivery system with great potential for use as a nano-carrier for a wide diversity of pharmaceutical applications.Entities:
Keywords: Albumin fusion technology; Cell-penetrating peptide; Drug binding; Human serum albumin; Macropinocytosis; Palmitate high affinity binding site
Mesh:
Substances:
Year: 2018 PMID: 29530390 DOI: 10.1016/j.jconrel.2018.02.037
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776